Top Trending Tickers On StockTwits For March 21
Here's a look at the top tickers trending on StockTwits.com.
Tiffany: Earnings miss
This morning, Tiffany & Co (NYSE: TIF) reported its fourth quarter results. The company announced an EPS of $1.47, missing the consensus estimate of $1.52. Revenue of $1.29 billion missed the consensus estimate of $1.31 billion.
Worldwide net sales rose five percent to $1.3 billion and comparable store sales rose six percent in the quarter. In the Americas region, total sales rose six percent to $659 million while comparable store sales rose seven percent in the quarter.
Tiffany posted a net loss in the quarter of $103.6 million compared to a net profit of $179.6 million in the same quarter last year. The company noted that it took a pretax charge of $473 million related to an arbitration case against Swatch.
Tiffany issued downside guidance and sees its full year 2014 EPS to be $4.05 to $4.15, below the consensus estimate of $4.28.
Shares were trading lower by 2.11 percent in the pre-market session.
Symantec: CEO shown the door
On Thursday, Symantec (NASDAQ: SYMC) announced that its CEO Steve Bennett has been relieved of his duties. Bennett's tenure with the company lasted less than two years as the company has underperformed as of late with a series of disappointing earnings and ongoing share losses.
Daniel Schulman, chairman of Symantec said that Bennett's firing “was the result of an ongoing deliberative process, and not precipitated by any event or impropriety”
Michael Brown has been named interim CEO.
Shares were trading lower by 9.11 percent in the pre-market session.
Darden Restaurants: Mixed earnings
This morning, Darden Restaurants (NYSE: DRI) reported its third quarter results. The company announced an EPS of $1.02, beating the consensus estimate of $1.82. Revenue of $2.23 billion missed the consensus estimate of $2.25 billion. Darden estimates that its earnings per share took a $0.07 hit due to severe weather which slowed down traffic and a $0.06 hit due to an implementation of a new strategic plan. Net earnings for the quarter fell to $109.7 million from $134.4 million in the same quarter last year.
U.S. same-restaurant sales increased 0.3% atLongHorn Steakhouse, declined 5.4% at Olive Garden, declined 8.8% atRed Lobster and declined 0.7% at the Specialty Restaurant Group.
Darden reaffirmed its full year fiscal 2014 guidance of a 15 percent to 20 percent decline in EPS, excluding any costs from its strategic plan that it announced in December.
Shares were trading lower by 2.18 percent in the pre-market session.
Endocyte: Phase 2b data sends shares soaring
Endocyte (NASDAQ: ECYT) announced that a Phase 2b TARGET trial has met the primary endpoint for the combination of vintafolide (EC145/MK-8109) and docetaxel in folate receptor (FR)-positive recurrent non-small cell lung cancer (NSCLC) patients.
"We are pleased with the results of this study, as the vintafolide/docetaxel combination showed meaningful activity in patients with recurrent NSCLC, meeting the primary endpoint of the trial," said Binh Nguyen, M.D., Ph.D., vice president of medical affairs at Endocyte. "This is our second randomized study in a very challenging indication, where vintafolide has met the primary endpoint when used in patients selected with the companion imaging agent etarfolatide."
Shares were surging by 121.65 percent in the pre-market session.
Nike: Positive earnings, poor guidance
Last night, Nike (NYSE: NKE) reported its third quarter results. The company announced an EPS of $0.76, beating the consensus estimate of $0.72. Revenue of $6.97 billion beat the consensus estimate of $6.69 billion.
Net income for the quarter rose three percent from last year $685 million while its gross margin rate rose 30 bps to 44.5 percent in the same time period. Nike noted that demand for footwear products were very strong in Europe and showed solid growth in the U.S. Sales of converse were particularly strong and rose 16 percent year over year to $420 million.
Nike stated during its conference call that it expects its fourth quarter revenue to grow by a high-single-digit percent year over year, below the consensus estimate for a 12.3 percent gain. The company is projecting its fiscal 2015 EPS growth to come in below its previous mid-teens target range and a consensus estimate of 16 percent EPS growth in fiscal 2015.
Shares were trading lower by 3.34 percent in the pre-market session.
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.